Oscar Health Q2 net income $361.8M, EPS $1.10; raises 2026 operating earnings outlook
Oscar Health reported second-quarter 2026 total revenue of $4.9 billion, up from $2.9 billion a year earlier, and net income attributable to the company of $361.8 million, or $1.10 per diluted share, compared with a loss of $228.4 million, or $(0.89) per share, in the second quarter of 2025. The company also raised its full-year 2026 earnings from operations guidance to $500 million to $700 million from $250 million to $450 million, which points to higher expected profitability for shareholders.
Key points
- Q2 2026 medical loss ratio was 79.2%, compared with 91.1% in Q2 2025, which the company attributed partly to $164 million of favorable prior period reserve development.
- Q2 2026 earnings from operations were $388.6 million, compared with a loss from operations of $230.5 million in Q2 2025.
- Full-year 2026 guidance for medical loss ratio was lowered to 81.5% to 82.5% from 82.4% to 83.4%, and total revenue guidance of $18.7 billion to $19.0 billion was unchanged.
- Effectuated membership was 2,963,002 as of June 30, 2026, compared with 2,027,148 a year earlier.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.